Infection and chemotherapy

The Korean Society of Infectious Diseases (대한감염학회)
권호 표지
DOI QR코드

DOI QR Code

Optimal Timing of Zoster Vaccination After Shingles: A Prospective Study of the Immunogenicity and Safety of Live Zoster Vaccine

  • Lee, Eunyoung (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Chun, June Young (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Song, Kyoung-Ho (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Choe, Pyoeng Gyun (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Bang, Ji Hwan (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Kim, Eu Suk (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Kim, Hong Bin (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Park, Sang Won (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Kim, Nam Joong (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Park, Wan Beom (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Oh, Myoung-don (Department of Internal Medicine, Seoul National University College of Medicine)
  • Received : 2018.08.05
  • Accepted : 2018.10.31
  • Published : 2018.12.31
⟨ Previous Next ⟩

Abstract

Background: Zoster vaccination is recommended for people with a history of herpes zoster (HZ), but the most effective timing of vaccine administration after zoster illness is unresolved. This prospective observational study compared the immunogenicity and safety of administering HZ vaccine at 6-12 months and 1-5 years after zoster illness. Materials and Methods: Blood samples were collected before the administration of live zoster vaccine and 6 weeks after vaccination. Varicella-zoster virus (VZV) IgG concentrations and T-cell responses were assessed by glycoprotein enzyme-linked immunosorbent assay and interferon-${\gamma}$ enzyme-linked immunospot assay (ELISPOT), respectively. Results: The baseline geometric mean value (GMV) of VZV IgG was higher in the 6-12 months group than in the 1-5 years group (245.5 IU/mL vs. 125.9 IU/mL; P = 0.021). However, the GMV increased significantly in both groups (P = 0.002 in the 6-12 months group; P <0.001 in the 1-5 years group). The results of the ELISPOT assay were not significant for differences of the GMV between baseline and 6-week post-vaccination groups, while the GMV increased significantly in both groups (P = 0.001 in the 6-12 months group; P <0.001 in the 1-5 years group). Conclusion: The immunogenicity of zoster vaccine may be similar whether administered 6-12 months, or >1 year after zoster illness. Trial Registration: ClinicalTrials.gov Identifier: NCT02704572

Keywords

References

  1. Bowsher D. The lifetime occurrence of herpes zoster and prevalence of post-herpetic neuralgia: a retrospective survey in an elderly population. Eur J Pain 1999;3:335-42. https://doi.org/10.1016/S1090-3801(99)90015-0
  2. van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009;27:1454-67. https://doi.org/10.1016/j.vaccine.2008.12.024
  3. Schmader K, Gnann JW Jr, Watson CP. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis 2008;197 (Suppl 2):S207-15. https://doi.org/10.1086/522152
  4. Cohen JI. Clinical practice: Herpes zoster. N Engl J Med 2013;369:255-63. https://doi.org/10.1056/NEJMcp1302674
  5. Yawn BP, Wollan PC, Kurland MJ, St Sauver JL, Saddier P. Herpes zoster recurrences more frequent than previously reported. Mayo Clin Proc 2011;86:88-93. https://doi.org/10.4065/mcp.2010.0618
  6. Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, Harpaz R. Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep 2018;67:103-8. https://doi.org/10.15585/mmwr.mm6703a5
  7. Mills R, Tyring SK, Levin MJ, Parrino J, Li X, Coll KE, Stek JE, Schlienger K, Chan IS, Silber JL. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine 2010;28:4204-9. https://doi.org/10.1016/j.vaccine.2010.04.003
  8. Tseng HF, Chi M, Smith N, Marcy SM, Sy LS, Jacobsen SJ. Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population. J Infect Dis 2012;206:190-6. https://doi.org/10.1093/infdis/jis334
  9. National Centre for Immunisation Research and Surveillance. The Australian immunisation handbook. 10th ed. Available at: http://www.practiceassist.com.au/PracticeAssist/media/ResourceLibrary/Programs%20and%20National%20Schemes/Immunise-The-Australian-Immunisation-Handbook-10th-Edition.pdf. Accessed 6 December, 2018.
  10. National Advisory Committee on Immunization. Update on the Use of Herpes Zoster Vaccine. Available at: https://www.canada.ca/en/public-health/services/publications/healthy-living/update-use-herpeszoster-vaccine.html?_ga=2.252998144.881335399.1517230152-1438438172.1517230152. Accessed December 6, 2018.
  11. Public Health England. Vaccination against shingles: 2015/16, Information for healthcare professionals. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/503099/PHE_Shingles_advice_for_health_professionals_2015-16__February2016_V4.pdf. Accessed 6 December, 2018.
  12. Kim JW, Min CK, Mun YC, Park Y, Kim BS, Nam SH, Koh Y, Kwon JH, Choe PG, Park WB, Kim I. Varicellazoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy. J Clin Virol 2015;73:64-9. https://doi.org/10.1016/j.jcv.2015.10.018
  13. Food and Drug Administration (FDA). Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. Rockville, MD: Botswana Government Print; 2007.
  14. Oxman MN. Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology 1995;45 (12 Suppl 8):S41-6. https://doi.org/10.1212/WNL.45.12_Suppl_8.S41
  15. Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, Caulfield MJ, Irwin MR, Smith JG, Clair J, Chan IS, Williams H, Harbecke R, Marchese R, Straus SE, Gershon A, Weinberg A; Veterans Affairs Cooperative Studies Program Shingles Prevention Study Investigators. Varicella-zoster virusspecific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008;197:825-35. https://doi.org/10.1086/528696
  16. Weinberg A, Zhang JH, Oxman MN, Johnson GR, Hayward AR, Caulfield MJ, Irwin MR, Clair J, Smith JG, Stanley H, Marchese RD, Harbecke R, Williams HM, Chan IS, Arbeit RD, Gershon AA, Schodel F, Morrison VA, Kauffman CA, Straus SE, Schmader KE, Davis LE, Levin MJ; US Department of Veterans Affairs (VA) Cooperative Studies Program Shingles Prevention Study Investigators. Varicella-zoster virusspecific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 2009;200:1068-77. https://doi.org/10.1086/605611
  17. Gilbert PB, Gabriel EE, Miao X, Li X, Su SC, Parrino J, Chan IS. Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve. J Infect Dis 2014;210:1573-81. https://doi.org/10.1093/infdis/jiu279
  18. Levin MJ, Schmader KE, Pang L, Williams-Diaz A, Zerbe G, Canniff J, Johnson MJ, Caldas Y, Cho A, Lang N, Su SC, Parrino J, Popmihajlov Z, Weinberg A. Cellular and humoral responses to a second dose of herpes zoster vaccine administered 10 years after the first dose among older adults. J Infect Dis 2016;213:14-22. https://doi.org/10.1093/infdis/jiv480
  19. Helgason S, Sigurdsson JA, Gudmundsson S. The clinical course of herpes zoster: a prospective study in primary care. Eur J Gen Pract 1996;2:12-6. https://doi.org/10.3109/13814789609161651
  20. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995;155:1605-9. https://doi.org/10.1001/archinte.1995.00430150071008
  21. Ragozzino MW, Melton LJ 3rd, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982;61:310-6. https://doi.org/10.1097/00005792-198209000-00003